The Regulatory Task Force focuses on understanding the global regulatory landscape and the impact it has on the ability to conduct PGx and other biomarker research in drug development. The group accomplishes this through activities that include, but are not limited to, investigating regulatory issues the industry faces via company surveys, reviewing and authoring publications that dive into the impact of country regulations on PGx and biomarker research, and gathering global information across the landscape to provide information for companies to improve their research capabilities.